Compare SBCF & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SBCF | DYN |
|---|---|---|
| Founded | 1926 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 3.0B |
| IPO Year | 2009 | 2020 |
| Metric | SBCF | DYN |
|---|---|---|
| Price | $32.75 | $20.13 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 14 |
| Target Price | $32.00 | ★ $37.00 |
| AVG Volume (30 Days) | 551.4K | ★ 1.8M |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.32% | N/A |
| EPS Growth | ★ 10.56 | N/A |
| EPS | ★ 1.57 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $45.04 | N/A |
| Revenue Next Year | $6.30 | N/A |
| P/E Ratio | $20.85 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $22.22 | $8.25 |
| 52 Week High | $35.55 | $25.00 |
| Indicator | SBCF | DYN |
|---|---|---|
| Relative Strength Index (RSI) | 63.23 | 60.89 |
| Support Level | $29.91 | $18.32 |
| Resistance Level | $33.04 | $21.00 |
| Average True Range (ATR) | 0.62 | 1.08 |
| MACD | 0.24 | 0.15 |
| Stochastic Oscillator | 77.26 | 66.31 |
Seacoast Banking Corp of Florida is a holding company. The company provides integrated financial services, including commercial and consumer banking, wealth management, and mortgage and insurance services, to customers across Florida through branch, mobile, and online banking solutions. It maintains day-to-day operations, particularly in the areas of operations, treasury management systems, information technology, and security. The company has one reportable segment that provides these integrated financial services, with segment revenues driven mainly by interest and fees on loans, interest on cash and cash equivalents, and investment securities, and fees on depository products and services.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease being treated, a linker, and an antigen-binding fragment that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.